Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
Abstract Human immunodeficiency virus (HIV) remains incurable due to latent viral reservoirs established in non-activated CD4 T cells that cannot be eliminated via antiretroviral therapy. Current efforts to cure HIV are focused on identifying drugs that will induce viral gene expression in latently...
Saved in:
Main Authors: | María Rosa López-Huertas, Carolina Gutiérrez, Nadia Madrid-Elena, Beatriz Hernández-Novoa, Julián Olalla-Sierra, Montserrat Plana, Rafael Delgado, Rafael Rubio, María Ángeles Muñoz-Fernández, Santiago Moreno |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/d1d63f1fdd2b4f53a1ec286acb22c2ef |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
by: María Rosa López-Huertas, et al.
Published: (2017) -
Reactivation of latent melioidosis presenting with acute pyelonephritis and bacteremia
by: Hamid Shaaban, et al.
Published: (2014) -
Latent virus reactivation in astronauts on the international space station
by: Satish K. Mehta, et al.
Published: (2017) -
Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
by: Thore Lorenzen
Published: (2010) -
Plateaus, rebounds and the effects of individual behaviours in epidemics
by: Henri Berestycki, et al.
Published: (2021)